Gramegran

Gramegran is an oral tablet containing the active ingredient sumatriptan succinate. It is a prescription medication marketed in the European Union and belongs to the selective serotonin (5‑HT1B/1D) receptor agonist class, commonly known as a triptan, used for the acute treatment of migraine attacks.

Gramegran is indicated for the acute management of migraine episodes in adults. It is not intended for prophylactic use or for other headache types.

- Treatment of a single migraine attack with onset of moderate to severe headache - Relief of associated migraine symptoms such as nausea, photophobia, and phonophobia - Can be used when other acute migraine therapies are ineffective - Suitable for patients who have previously responded to triptan therapy - Not recommended for chronic daily headache or cluster headache

Side effects of Gramegran vary in frequency and severity. Common reactions are usually mild and transient, while serious events are rare but require medical attention.

Common: - Tingling or numbness in fingers or toes - Warmth or flushing sensation - Dizziness or light‑headedness - Fatigue or drowsiness - Dry mouth - Nausea

Serious: - Chest pain or pressure - Severe hypertension - Serotonin syndrome (when combined with other serotonergic agents) - Allergic reactions such as rash, swelling, or difficulty breathing

Before using Gramegran, certain health considerations should be reviewed to minimize risks.

- Assess cardiovascular history, including coronary artery disease or uncontrolled hypertension - Evaluate for history of stroke, transient ischemic attack, or other cerebrovascular disorders - Consider potential for medication overuse headache with frequent dosing - Use caution in patients with hepatic or renal impairment - Discuss pregnancy or breastfeeding status with a healthcare professional - Review any prior adverse reactions to triptans or similar agents

Gramegran may interact with other medications, affecting its safety or efficacy. Some combinations should be avoided, while others require careful monitoring.

Avoid: - Other triptans or ergotamine derivatives - Monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs) due to risk of serotonin syndrome - Certain antihypertensive agents (e.g., ergot alkaloids) that may increase vasospasm risk

Use with caution: - Antidepressants that affect serotonin levels - CYP3A4 inhibitors such as ketoconazole or erythromycin - Medications that prolong QT interval - NSAIDs that may increase cardiovascular risk when combined